De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Serina Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Serina Therapeutics's earnings have been declining at an average annual rate of -687.1%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 2368.9% per year.
Belangrijke informatie
-687.1%
Groei van de winst
-414.4%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | -14.6% |
| Inkomstengroei | 2,368.9% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -220.9% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Serina Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -7 | 6 | 0 |
| 31 Mar 24 | 3 | -11 | 5 | 0 |
| 31 Dec 23 | 3 | 5 | 4 | 0 |
| 30 Sep 23 | 0 | 4 | 2 | 0 |
| 30 Jun 23 | 0 | 1 | 2 | 0 |
| 31 Mar 23 | 0 | 0 | 2 | 0 |
| 31 Dec 22 | 1 | -3 | 1 | 0 |
| 31 Dec 21 | 3 | -1 | 1 | 0 |
Kwaliteitswinsten: 2BO is currently unprofitable.
Groeiende winstmarge: 2BO is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Insufficient data to determine if 2BO's year-on-year earnings growth rate was positive over the past 5 years.
Versnelling van de groei: Unable to compare 2BO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 2BO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Rendement op eigen vermogen
Hoge ROE: 2BO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.